Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes.

ABSTRACT

Prophylaxis with palivizumab has been shown to decrease hospitalizations in at-risk infants. Compliance was higher with a home-based rather than a clinic-based system and was associated with decreased hospitalizations and unscheduled medical visits. Home-based delivery of respiratory syncytial virus prophylaxis may be more efficacious in preventing disease through increased compliance and decreased exposure of the high-risk infant to the clinic environment.